<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02263131</url>
  </required_header>
  <id_info>
    <org_study_id>IY_IFEZ_CH_301</org_study_id>
    <nct_id>NCT02263131</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children</brief_title>
  <official_title>Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to &lt; 18 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated
      Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single
      intramuscular injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multi-center, randomized, double-blind, active-controlled study.

      Before initiation of any protocol-specific activities, written informed consent was obtained
      from each patient and their legally acceptable representatives (consent of the legally
      acceptable representative was required for children younger than 10 years of age, and for the
      some sites, for children younger than 7 years of age). Subjects who met all of the
      eligibility criteria after screening assessments as specified in the protocol, were
      randomized into the test group or the comparator group in a ratio of 5 to 1 according to the
      pre-generated site-specific randomization table, and received a single dose or two doses of
      the study vaccine. The investigator performed the efficacy (immunogenicity) and safety
      assessments throughout the study. Efficacy data were collected at Visit 1 (prior to
      vaccination) and at the end-of-study visit for efficacy (immunogenicity) assessments, and for
      safety assessment, subjects and their legally acceptable representatives were instructed to
      record any treatment-emergent adverse event in Patient Diary cards.

      For all randomized subjects, blood sample was obtained prior to vaccination, and the study
      vaccine 0.5mL or 0.25mL was administered to the deltoid muscle or anterolateral thigh muscle.
      For children aged from 6 months to &lt;9 years of age who had not been previously exposed to
      influenza virus or had not previously received influenza vaccine, another dose of the study
      vaccine was administered 4 to 5 weeks after the first dose. Blood samples were collected 4 to
      5 weeks after the last dose of the study drug for the assessment of antibody titer. All
      subjects were followed for 6 months after the last dose of the study drug for the safety
      assessments, and Month 6 follow-up visit was the end-of-study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited Local &amp; General Adverse Event, Unsolicited Adverse Event</measure>
    <time_frame>up to Day28(+7)</time_frame>
    <description>Solicited local reaction: pain, tenderness, redness, swelling Solicited general reactions: fever, nausea/vomiting, diarrhea, headache, fatigue, myalgia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving Seroconversion and Seroprotection for HI Antibody After Administration of the Study Vaccine</measure>
    <time_frame>up to Day28(+7)</time_frame>
    <description>Seroconversion: a pre-vaccination (Day 0) hemagglutination-inhibition (HI) antibody titer &lt; 1:10 and a post-vaccination (last vaccination + Day 28) HI antibody titer ≥ 1: 40 (Case 1), or a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (last vaccination + Day 28) HI antibody titer (Case 2), * Seroprotection: post-vaccination (Day 28) HI antibody titer ≥ 1:40</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical Examination Finding, Vital Signs</measure>
    <time_frame>Day28(+7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of HI Antibody Titer Before Vaccination and After Vaccination</measure>
    <time_frame>Day28(+7)</time_frame>
    <description>Geometric Mean Titer (GMT), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMR of HI Antibody Titer Before Vaccination and After Vaccination</measure>
    <time_frame>Day28(+7)</time_frame>
    <description>Geometric Mean Ratio (GMR), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer &lt; 1:40, and a Minimum Four-fold Rise in Post-vaccination (Day 28) HI Antibody Titer</measure>
    <time_frame>Day28(+7)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IL-YANG PFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IL-YANG FLU Vaccine Prefilled Syringe INJ.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV PFS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAXIGRIP Prefilled Syringe INJ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IL-YANG FLU Vaccine Prefilled Syringe INJ.</intervention_name>
    <description>IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL</description>
    <arm_group_label>IL-YANG PFS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAXIGRIP Prefilled Syringe INJ.</intervention_name>
    <description>VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL</description>
    <arm_group_label>TIV PFS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men or women aged from 6 months to &lt; 18 years

          -  Subjects were born after full term pregnancy (37 weeks)

          -  Voluntary written informed consent was obtained from the subject and the subject's
             legally acceptable representative (consent of legally acceptable representative was
             required for subjects younger than 10 years of age (and for subjects younger than 7
             years of age for the some institutions)).

        Exclusion Criteria:

          -  Subject with a known allergy to eggs, chicken, neomycin, gentamicin or any components
             of the study vaccine

          -  Subject who had received an influenza vaccine within the last 6 months

          -  Subject who has, or has a family history of, an immune system disorder including
             immune deficiency disease

          -  Subject with a history of Guillain-Barre syndrome

          -  Subject with Down's syndrome or cytogenetic disorders.

          -  Subject with severe chronic disease which in the investigator's opinion would not make
             the subject a good candidate for the clinical trial

          -  Subject with hemophilia or being treated with an anticoagulant, who are at increased
             risk of serious bleeding during intramuscular injection

          -  Subject who had an acute fever with body temperature &gt; 38.0 Cº within 72 hours prior
             to administration of the study vaccine

          -  Subject who had previously received another vaccine within 28 days before
             administration of the study drug, or is scheduled to receive another vaccine during
             the study period.

          -  Subject who had received immunosuppressant or immune modifying drug within the last 3
             months prior to administration of the study vaccine

          -  Subject who had previously received immunoglobulin or blood-derived products within
             the last 3 months prior to administration of the study vaccine, or is expecting to be
             treated with immunoglobulin or blood-derived products during the study.

          -  Subject who had participated in another experimental study within 30 days prior to
             administration of the study vaccine

          -  Subject with other clinically significant medical or psychological condition who in
             the investigator's opinion would not be suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Han Kang, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <results_first_submitted>March 26, 2015</results_first_submitted>
  <results_first_submitted_qc>March 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2015</results_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Influenza vaccine</keyword>
  <keyword>Split influenza vaccine</keyword>
  <keyword>Seasonal influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IL-YANG PFS</title>
          <description>IL-YANG FLU Vaccine Prefilled Syringe INJ.
IL-YANG FLU Vaccine Prefilled Syringe INJ.: IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL</description>
        </group>
        <group group_id="P2">
          <title>TIV PFS</title>
          <description>VAXIGRIP Prefilled Syringe INJ.
VAXIGRIP Prefilled Syringe INJ.: VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="347"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IL-YANG PFS</title>
          <description>IL-YANG FLU Vaccine Prefilled Syringe INJ.
IL-YANG FLU Vaccine Prefilled Syringe INJ.: IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL</description>
        </group>
        <group group_id="B2">
          <title>TIV PFS</title>
          <description>VAXIGRIP Prefilled Syringe INJ.
VAXIGRIP Prefilled Syringe INJ.: VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="347"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="416"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.83" spread="4.87"/>
                    <measurement group_id="B2" value="7.45" spread="5.01"/>
                    <measurement group_id="B3" value="7.77" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Solicited Local &amp; General Adverse Event, Unsolicited Adverse Event</title>
        <description>Solicited local reaction: pain, tenderness, redness, swelling Solicited general reactions: fever, nausea/vomiting, diarrhea, headache, fatigue, myalgia</description>
        <time_frame>up to Day28(+7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG PFS</title>
            <description>IL-YANG FLU Vaccine Prefilled Syringe INJ.
IL-YANG FLU Vaccine Prefilled Syringe INJ.: IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL</description>
          </group>
          <group group_id="O2">
            <title>TIV PFS</title>
            <description>VAXIGRIP Prefilled Syringe INJ.
VAXIGRIP Prefilled Syringe INJ.: VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local &amp; General Adverse Event, Unsolicited Adverse Event</title>
          <description>Solicited local reaction: pain, tenderness, redness, swelling Solicited general reactions: fever, nausea/vomiting, diarrhea, headache, fatigue, myalgia</description>
          <units>percentage of paticipants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.88" lower_limit="64.00" upper_limit="73.75"/>
                    <measurement group_id="O2" value="76.81" lower_limit="66.85" upper_limit="86.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving Seroconversion and Seroprotection for HI Antibody After Administration of the Study Vaccine</title>
        <description>Seroconversion: a pre-vaccination (Day 0) hemagglutination-inhibition (HI) antibody titer &lt; 1:10 and a post-vaccination (last vaccination + Day 28) HI antibody titer ≥ 1: 40 (Case 1), or a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (last vaccination + Day 28) HI antibody titer (Case 2), * Seroprotection: post-vaccination (Day 28) HI antibody titer ≥ 1:40</description>
        <time_frame>up to Day28(+7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IL-YANG PFS</title>
            <description>IL-YANG FLU Vaccine Prefilled Syringe INJ.
IL-YANG FLU Vaccine Prefilled Syringe INJ.: IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL</description>
          </group>
          <group group_id="O2">
            <title>TIV PFS</title>
            <description>VAXIGRIP Prefilled Syringe INJ.
VAXIGRIP Prefilled Syringe INJ.: VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving Seroconversion and Seroprotection for HI Antibody After Administration of the Study Vaccine</title>
          <description>Seroconversion: a pre-vaccination (Day 0) hemagglutination-inhibition (HI) antibody titer &lt; 1:10 and a post-vaccination (last vaccination + Day 28) HI antibody titer ≥ 1: 40 (Case 1), or a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (last vaccination + Day 28) HI antibody titer (Case 2), * Seroprotection: post-vaccination (Day 28) HI antibody titer ≥ 1:40</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion: H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.02" lower_limit="56.84" upper_limit="67.20"/>
                    <measurement group_id="O2" value="55.88" lower_limit="44.08" upper_limit="67.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion: H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.41" lower_limit="48.09" upper_limit="58.74"/>
                    <measurement group_id="O2" value="57.35" lower_limit="45.60" upper_limit="69.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.90" lower_limit="49.58" upper_limit="60.21"/>
                    <measurement group_id="O2" value="66.18" lower_limit="54.93" upper_limit="77.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection: H1N1 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.96" lower_limit="92.62" upper_limit="97.29"/>
                    <measurement group_id="O2" value="89.71" lower_limit="82.48" upper_limit="96.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection: H3N2 strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.77" lower_limit="91.19" upper_limit="96.35"/>
                    <measurement group_id="O2" value="91.18" lower_limit="84.43" upper_limit="97.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection: B strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.25" lower_limit="92.98" upper_limit="97.52"/>
                    <measurement group_id="O2" value="95.59" lower_limit="90.71" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Examination Finding, Vital Signs</title>
        <time_frame>Day28(+7)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of HI Antibody Titer Before Vaccination and After Vaccination</title>
        <description>Geometric Mean Titer (GMT), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.</description>
        <time_frame>Day28(+7)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMR of HI Antibody Titer Before Vaccination and After Vaccination</title>
        <description>Geometric Mean Ratio (GMR), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.</description>
        <time_frame>Day28(+7)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer &lt; 1:40, and a Minimum Four-fold Rise in Post-vaccination (Day 28) HI Antibody Titer</title>
        <time_frame>Day28(+7)</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IL-YANG PFS</title>
          <description>IL-YANG FLU Vaccine Prefilled Syringe INJ.
IL-YANG FLU Vaccine Prefilled Syringe INJ.: IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL</description>
        </group>
        <group group_id="E2">
          <title>TIV PFS</title>
          <description>VAXIGRIP Prefilled Syringe INJ.
VAXIGRIP Prefilled Syringe INJ.: VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="347"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kang Jin Han</name_or_title>
      <organization>The Catholic University of Korea, Seoul St. Mary’s Hospital</organization>
      <phone>+82-10-4251-8375</phone>
      <email>kjhan@catholic.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

